Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Dexamethasone + Fludrocortisone + ODM-208 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Dexamethasone | Adexone | Desametasone | ||
| Fludrocortisone | Florinef Acetate | |||
| ODM-208 | ODM208|ODM 208|MK-5684|MK5684|MK 5684|Opevesostat | ODM-208 is a selective inhibitor of CYP11A1, which potentially inhibits steroid biosynthesis and tumor growth (PMID: 36129801). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06979596 | Phase II | Megestrol acetate Tamoxifen Exemestane Dexamethasone + Fludrocortisone + ODM-208 Fulvestrant Letrozole | A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Recruiting | USA | GBR | ESP | BRA | ARG | 4 |
| NCT06136624 | Phase III | Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide Abiraterone + Prednisone | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (OMAHA-003) | Recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | AUT | AUS | ARG | 13 |
| NCT06136650 | Phase III | Abiraterone + Prednisone Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide | A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Recruiting | USA | TUR | SWE | SVK | ROU | NZL | LVA | LTU | ITA | ISR | IRL | HUN | GRC | GBR | FRA | EST | ESP | DEU | CZE | CAN | BRA | AUS | 17 |